Nakanishi T, Kanazawa I, Goto I, Iwata M, Kowa H, Mannen T, Mizuno Y, Nishitani H, Ogawa N, Takahashi A
Institute of Clinical Medicine, University of Tsukuba, Japan.
Eur Neurol. 1990;30 Suppl 1:3-8. doi: 10.1159/000117167.
The interim results obtained up to the end of the 3rd year of the multicenter nationwide cooperative study on the long-term effects of bromocriptine in parkinsonian patients are reported. Bromocriptine monotherapy could be continued in approximately 33% of the patients at the mean maintenance dose of 11.4 mg/day. The combined use of bromocriptine (11.1 mg/day) in parkinsonian patients already treated with levodopa had a favorable influence on the long-term side effects of levodopa such as the on-off phenomenon and dyskinesia. The beneficial effects of bromocriptine, levodopa and an early combination on parkinsonian symptoms such as rigidity and tremor remained at the end of the 3rd year. However, the effects of each mode of therapy on another parkinsonian symptom, akinesia, ceased by the end of the 3rd year.
本文报告了一项关于溴隐亭对帕金森病患者长期影响的多中心全国性合作研究截至第3年末的中期结果。约33%的患者能够以平均维持剂量11.4毫克/天继续使用溴隐亭单药治疗。在已接受左旋多巴治疗的帕金森病患者中联合使用溴隐亭（11.1毫克/天），对左旋多巴的长期副作用如开关现象和运动障碍有积极影响。在第3年末，溴隐亭、左旋多巴以及早期联合用药对帕金森病症状如强直和震颤的有益作用依然存在。然而，到第3年末，每种治疗方式对另一帕金森病症状——运动不能的疗效消失。
